References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.
- Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, et al.. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol. 2012;6:199–208.
- Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al.. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
- Casaretto L, Sousa PL, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res. 2006;39:431–40.
- Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011;12:96–106.
- Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al.. A randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.
- Ross P, Cunningham D, Scarffe H. Results of a randomized trial comparing ECF with MCF in advanced esophagogastric cancer. Proc Am Soc Clin Oncol. 1999;18:272a(abstr1042).
- Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.
- Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al.. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–7.
- Cunningham D, Starling N, Rao S, Lveson T, Nicolson M, Coxon F, et al.. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
- Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al.. Phase III study of docetaxel and cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.
- AI-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al.. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42.
- Therasse P, Arbuck SG, Eisenhaur EA, Wanders J, Kaplan RS, Rubinstein L, et al.. New guidelines to evaluate the response to treatment in solid tumors. Cancer Institute of the United states, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
- Long N, Moore MA, Chen W, Gao CM, Lai MS, Mizoue T, et al.. Cancer epidemiology and control in north-East Asia-past, present and future. Asian Pac J Cancer Prev. 2010;11:107–48.
- Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al.. Gastric cancer. J Natl Compr Canc Netw. 2010;8:378–409.
- Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al.. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.
- Inal A, Kaplan MA, Kucukoner M, Isikdogan A. Docetaxel and Cisplatin plus Fluorouracil compared with modified docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma. 2012;59:233–6.
- Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, et al.. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer. 2012;15:49–55.
- Killckap S, Yalcin S, Ates O, Tekuzman G. The first line systemic chemotherapy in metastatic gastric carcinoma: a comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting. Hepatogastroenterology. 2011;58:208–12.